Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

Background Recurrent and/or metastatic (R/M) disease develops in approximately 65% of patients with squamous cell carcinoma of the head and neck (SCCHN) and is associated with a poor prognosis. Immune checkpoint inhibitors have proven effective in multiple tumor types, including R/M SCCHN. We report...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicolas Penel, Ulrich Keilholz, Ani Balmanoukian, Manish R Patel, Sanjay Goel, Keun-Wook Lee, Alain Mita, Christophe Le Tourneau, Deborah J Wong, Patrick Schöffski, Marcis Bajars, Amaury Daste, Hans Juergen Grote, Dongli Zhou, Michael S Gordon, Martin Gutierrez, Damien Vansteene, Joël Guigay
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e002998.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/9/10/e002998.full

Similar Items